Abstract 12P
Background
Although cancer is the second leading cause of death in the world, many cancer types including breast cancer, cervical cancer, lung cancer, and colorectal cancer can be efficiently treated if detected in their early stages, thus offering increased survival rates. Because of the ability of reflection from tumor tissue origin and systemic host response, plasma cell-free RNA (cfRNA) emerges as a highlight candidate. Previous studies have shown that plasma circulating tumor DNA (ctDNA) can serve as a potential biomarker for early detection of cancer. However, ctDNA-based assays demonstrated low sensitivity for the detection of breast cancer due to the low fraction and molecular heterogeneity of ctDNA. Unlike ctDNA, plasma cfRNA is released from the tumor microenvironment into circulation not only via cell death but also through cell-cell communication mechanisms. Cell-free mRNA (cfmRNA) is a subtype of cfRNA and its expression has been shown to reflect the transcriptomic alterations not only in tumor cells but also in other cell types in tumor microenvironments. Therefore, cfmRNAs have emerged as potential biomarkers for the early detection of breast cancer.
Methods
Here, we comprehensively profiled the cfmRNA transcriptome of breast cancer patients (n=24) and healthy individuals (n=33) by next-generation sequencing and identified differentially expressed cfmRNAs (DEM) by Deseq2. We further performed pathway enrichment analysis by the profiler, thus confirming their functional contribution to breast tumorigenesis.
Results
We found the set of 10955 DEMs, including breast-cancer markers like LAMP3, HSD11B1, PRTG, LPL, and identified 49 significantly enriched pathways. Interestingly, we discovered some DEMs (CD3D, CD8B, CD274, CTLA4, FOXP3, IL2RA) related to the distribution and function of tumor-infiltrating lymphocytes. Importantly, we demonstrated that the combination of tumor-specific and lymphocyte-related DEMs could differentiate blood samples of breast cancer patients and those of healthy individuals.
Conclusions
Our findings provide implications for the clinical utility of cfmRNAs for early detection of cancer types shedding low amounts of ctDNA such as breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute, Ho Chi Minh, Vietnam.
Funding
Gene Solutions Joint Stock Company.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract